Influence of Family History of Breast or Ovarian Cancer on Pathological Complete Response and Long-Term Prognosis in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.
Breast cancer
Family history
Neoadjuvant chemotherapy
Ovarian cancer
Pathological complete response
Prognosis
Journal
Breast care (Basel, Switzerland)
ISSN: 1661-3791
Titre abrégé: Breast Care (Basel)
Pays: Switzerland
ID NLM: 101254060
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
received:
11
09
2019
accepted:
24
03
2020
entrez:
12
7
2021
pubmed:
13
7
2021
medline:
13
7
2021
Statut:
ppublish
Résumé
In breast cancer, a pathological complete response (pCR) has been described as generally resulting in a favorable prognosis. However, there are subgroups, such as patients with a mutation in Breast cancer patients were identified from a clinical breast cancer registry. The study subjects had been treated with neoadjuvant chemotherapy from 2001 to 2018 and their pathological and clinical information as well as medical family history were available. They were considered to have a positive family history if they had at least 1 first-degree relative with breast and/or ovarian cancer. Multivariate logistic regression analyses were performed to study the association between family history, pCR (ypT0; ypN0), and disease-free survival (DFS). Of 1,480 patients, 228 (15.4%) had a positive family history. The pCR rates were 24.9% in all patients, and 24.4% and 27.6% in those without/with a family history, respectively. Family history was not associated with a higher pCR rate (adjusted odds ratio [OR] 1.23; 95% confidence interval [CI] 0.85-1.76; In this retrospective analysis, family history was not associated with pCR and DFS. pCR improved survival, independently of family history.
Identifiants
pubmed: 34248466
doi: 10.1159/000507475
pii: brc-0016-0254
pmc: PMC8248781
doi:
Types de publication
Journal Article
Langues
eng
Pagination
254-262Informations de copyright
Copyright © 2020 by S. Karger AG, Basel.
Déclaration de conflit d'intérêts
M.P.L. reports personal fees from Pfizer, Roche, Merck Sharp & Dohme, Hexal, Novartis, AstraZeneca, Tesaro, Eisai, medac, and Lilly. C.C.H. reports personal fees from Roche. N.N. reports personal fees from Janssen-Cilag, Novartis, and Teva. A. Hartmann reports personal fees from Bristol-Myers Squibb, Roche, Merck Sharp & Dome, Novartis, AstraZeneca, NanoString, BioNTech, and Janssen-Cilag. P.A.F. reports research grants from Novartis and BioNTech and personal fees from Novartis, Roche, Pfizer, Celgene, Daiichi-Sankyo, TEVA, AstraZeneca, Puma, Eisai, Merck Sharp & Dohme, and Myelo Therapeutics. P.G. reports personal fees from Novartis, Roche, and PharmaMar. All the other authors declare that they have no conflicts of interest.
Références
Breast Cancer Res Treat. 2014 Apr;144(2):397-403
pubmed: 24557336
Geburtshilfe Frauenheilkd. 2018 Mar;78(3):237-245
pubmed: 29576629
Lancet Oncol. 2015 Jun;16(6):638-44
pubmed: 25959805
J Clin Oncol. 2012 Dec 10;30(35):4308-16
pubmed: 23109706
Geburtshilfe Frauenheilkd. 2012 Aug;72(8):727-733
pubmed: 25258465
JAMA Oncol. 2017 Sep 1;3(9):1190-1196
pubmed: 28418444
Onkologie. 2011;34(7):362-7
pubmed: 21734422
BMC Cancer. 2011 Nov 14;11:486
pubmed: 22081974
PLoS One. 2015 Mar 27;10(3):e0120189
pubmed: 25816289
J Clin Oncol. 2018 Aug 1;36(22):2281-2287
pubmed: 29791287
J Natl Cancer Inst. 2014 Jun;106(6):dju091
pubmed: 24824314
Hum Mol Genet. 2012 Sep 1;21(17):3926-39
pubmed: 22532573
J Clin Oncol. 2010 Jan 20;28(3):375-9
pubmed: 20008645
J Clin Oncol. 2008 Sep 1;26(25):4072-7
pubmed: 18757321
Breast Cancer Res Treat. 2018 Apr;168(2):513-521
pubmed: 29247441
J Cell Biochem. 2017 Dec;118(12):4728-4734
pubmed: 28513990
JAMA Oncol. 2017 Oct 1;3(10):1378-1385
pubmed: 28715532
Geburtshilfe Frauenheilkd. 2018 Nov;78(11):1056-1088
pubmed: 30581198
Breast Cancer Res Treat. 2016 May;157(1):157-65
pubmed: 27113739
Nat Genet. 2013 Apr;45(4):353-61, 361e1-2
pubmed: 23535729
Medicine (Baltimore). 2016 Oct;95(40):e4975
pubmed: 27749552
Geburtshilfe Frauenheilkd. 2019 May;79(5):470-482
pubmed: 31148847
Geburtshilfe Frauenheilkd. 2018 Oct;78(10):927-948
pubmed: 30369626
N Engl J Med. 2007 Jul 12;357(2):115-23
pubmed: 17625123
Breast Cancer Res Treat. 2014 Nov;148(1):143-51
pubmed: 25253172
Nat Genet. 2013 Apr;45(4):371-84, 384e1-2
pubmed: 23535731
J Clin Oncol. 2012 May 20;30(15):1796-804
pubmed: 22508812
J Clin Oncol. 2012 Jan 1;30(1):19-26
pubmed: 22147742
BMC Cancer. 2018 Mar 22;18(1):315
pubmed: 29566657
Breast Cancer Res Treat. 2018 Aug;171(1):85-94
pubmed: 29725888
Clin Cancer Res. 2011 Mar 1;17(5):1082-9
pubmed: 21233401
BMC Cancer. 2018 Oct 29;18(1):1051
pubmed: 30373556
Geburtshilfe Frauenheilkd. 2013 Dec;73(12):1228-1235
pubmed: 24771903
Breast Cancer Res Treat. 2008 Nov;112(1):89-98
pubmed: 18049890
BMC Cancer. 2010 Mar 10;10:90
pubmed: 20219108
Geburtshilfe Frauenheilkd. 2019 Mar;79(3):256-267
pubmed: 30880824
Clin Cancer Res. 2015 Jan 1;21(1):211-20
pubmed: 25348513
J Clin Oncol. 2013 Sep 10;31(26):3191-6
pubmed: 23940229
J Clin Oncol. 2015 Feb 1;33(4):304-11
pubmed: 25452441
Geburtshilfe Frauenheilkd. 2018 May;78(5):481-492
pubmed: 29880983
Lancet. 2014 Jul 12;384(9938):164-72
pubmed: 24529560
Breast Cancer Res Treat. 2011 Jan;125(1):145-56
pubmed: 21042932
Ann Oncol. 2009 Aug;20(8):1319-29
pubmed: 19535820
Science. 2014 Mar 28;343(6178):1466-70
pubmed: 24675953
Fam Cancer. 2017 Jul;16(3):339-349
pubmed: 28176206
Lancet Oncol. 2018 Feb;19(2):169-180
pubmed: 29337092
J Clin Oncol. 2010 Jun 1;28(16):2784-95
pubmed: 20404251
J Clin Oncol. 2011 Oct 1;29(28):3739-46
pubmed: 21900106
PLoS Genet. 2013;9(3):e1003212
pubmed: 23544013
Breast Cancer Res Treat. 2014 May;145(1):193-203
pubmed: 24682655